About us

“We decided to create PDC*line Pharma to transform over a decade of research at the French Blood Bank (EFS) into a new generation of potent and scalable active immunotherapies for cancer patients.” – Laurent Levy (MS, MBA) and Joel Plumas (PhD), co-founders.

Our mission

PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens.

PDC*mel, our first drug candidate is currently in phase 1 clinical trials for melanoma. PDC*lung is in preclinical development for lung cancer.

Our approach can be applied to virtually any type of cancer and any patient population, and combined with differents cancer treatments.

pdcline_our_mission

Our history

PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Français du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia.

Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.

Key milestones

July 2016

Foundation of PDC line Pharma SA, Belgium holding based in Liège (Belgium), headed by Eric Halioua, President & CEO.

June 2015

ATMP classification granted by EMA for PDC*vac class of active immunotherapies for cancer

February 2015

2015 Life Sciences Grand Prize of the French start-up competition Tremplin Entreprises

January 2015

Exclusive licensing rights from the French Blood Bank (EFS)

December 2014

Award of “Réseau Entreprendre”

September 2014

Dr Isabelle Tabah-Fisch joins PDC*line Pharma as Chief Medical Officer

June 2014

Laureate of the Worldwide Innovation Challenge 2030

June 2014

Laureate of the i-LAB French national competition for the creation of innovative technologies companies

April 2014

Foundation of PDC*line Pharma

June 2013

GATE1 Grenoble incubator award winner

June 2013

Start of the phase 1 first-in-man clinical trial in melanoma

Our team

Management

Eric HALIOUA (MS, MBA), Chief Executive Officer

Eric is former CEO of Promethera Biosciences, co-founder of Myosix (sold to Genzyme/Sanofi) & Murigenetics ; Board member of Bioxodes (Belgium), and member of the strategic advisory board of OncoDNA (Belgium), Innobiochips (France) and the CER Groupe (Belgium). He has also been principal of the international life sciences practice of Arthur D. Little based (Paris, Boston).

Laurent LEVY (MS, Exec. MBA), Co-founder, President France & Chief Operating Officer

Laurent has over 20 years of experience in funding and development of innovative and entrepreneurial ecosystems and projects in biotech and oncology. He was previously director of Finance and Development of a french leader cluster in oncology (CLARA) where he managed a fund that supported 30 preclinical and clinical proof-of-concept projects with biotech companies.

Joel PLUMAS (PhD), Co-founder & Chief Scientific Officer

Joel is immunologist and co-inventor of the PDC*vac technology. He was director the “Immunobiology and Immunotherapy of cancers” R&D lab of the French blood bank (EFS) where he coordinated the development of the project from bench to bedside, including IP, manufacturing and regulatory aspects.

Beatrice DE VOS (MD, PhD, BCPM), Chief Medical Officer

Beatrice has 25 years of leading positions of clinical research and medical affairs of major pharmaceutical companies (Regional Director at Wyeth-Ayerst R&D, VP Global Medical Affairs at GSK Biologicals, VP Global Medical & Scientific Affairs at Sanofi Pasteur). She was in charge of the clinical development of multiple drug and viral vaccine candidates. She is also advisor to national and international companies and NGO’s.

Claude DEDRY (Pharm. D), VP Pharmaceutical Operations & Quality

Claude has over 25 years of experience in GMP manufacturing and quality control operations of vaccines and cell therapies (GSK vaccines, Promethera Biosciences…). He is owner of CMDL Consulting (Belgium) that provides small, medium and big size companies with guidance in this area.

 

Board of Directors

Eric HALIOUA (MS, MBA), President of the Board

Eric is former CEO of Promethera Biosciences, co-founder of Myosix (sold to Genzyme/Sanofi) & Murigenetics ; Board member of Bioxodes (Belgium), and member of the strategic advisory board of OncoDNA (Belgium), Innobiochips (France) and the CER Groupe (Belgium). He has also been principal of the international life sciences practice of Arthur D. Little based (Paris, Boston).

Laurent LEVY (MS, Exec. MBA), Director

Laurent has over 20 years of experience in funding and development of innovative and entrepreneurial ecosystems and projects in biotech and oncology. He was previously director of Finance and Development of a french leader cluster in oncology (CLARA) where he managed a fund that supported 30 preclinical and clinical proof-of-concept projects with biotech companies.

Joel PLUMAS (PhD), Director

Joel is immunologist and co-inventor of the PDC*vac technology. He was director the “Immunobiology and Immunotherapy of cancers” R&D lab of the French blood bank (EFS) where he coordinated the development of the project from bench to bedside, including IP, manufacturing and regulatory aspects.

A_Herrera

Alain HERRERA (Medical Oncologist), Director

Alain HERRERA, Medical Oncologist, has over 25 years of experience in the pharmaceutical industry with a strong focus on oncology drug development and marketing. He was head of the global oncology franchise at Sanofi Aventis until 2007, where he contributed to the worldwide registration of a number of major cancer drugs.

jean-paul-prieels

Jean-Paul PRIEELS (PhD), Director

Jean-Paul served as a Senior Vice President of Research and Development at GSK Vaccines and founded Masthercell. He is board member of numerous biotechs including Okarios, Vaximm, Curevac, Nouscom…

Joanna TYREKIDIS (MBA), Director

Joanna is Investment Manager at Meusinvest. She has 12 years of experience in project management, international trade and business consulting in Belgium, Luxembourg, Jordan and Iraq.

Scientific advisory board

C_Caux

Christophe CAUX (PhD)

Christophe is Director of Research (Inserm) and co-head of a research team at the Lyon Cancer Research Centre (CRCL) located in the Leon Berard Cancer Centre Hospital. He is an expert in dendritic cells, including the plasmacytoid subset, and develops a translational research program in tumour immunology and immunotherapy strategies.

P_Coulie

Pierre COULIE, (MD, PhD)

Pierre is a Professor at the University of Louvain and member of the Belgian Royal Academy of Medicine. He leads a research group at the de Duve Institute. He is an expert in cytotoxic responses against tumour antigens.

Thierry LE CHEVALIER (Medical Oncologist)

Thierry is Head of the Institute of Thoracic Oncology (Gustave Roussy Hospital), Paris Sud, and Associate Professor at the College of Medicine of Paris Hospitals. He is an expert in therapeutic strategies and translational research applied to lung cancer.

C_Leclerc

Claude LECLERC (PhD)

Claude is a Professor at the Pasteur Institute (Paris) and heads the “Immune Regulation and Vaccinology” research unit (Pasteur Institute) and the Inserm Unit U1041. She received the Georges, Jacques and Elias Canetti award in 2012 and an award from the  Yvelines General Council in 2013. She is an expert in vaccinology, cancer vaccines and the biology of dendritic cells, including the plasmacytoid subset.

 

Our partners

Research & development

partner-don-du-sang


EFS 

(Etablissement Français du Sang – French Blood Bank) transferred the PDC*vac technology to PDC*line Pharma, and provides us with privileged access to its research and GMP-compliant manufacturing infrastructures.

 


CHU Grenoble
University teaching hospital of Grenoble is sponsor of the phase 1 clinical trial of PDC*mel in advanced melanoma.

Support & Membership

 


bpifrance financements
The French public investment bank for entrepreneurs.

pdcline_lyonbiopole


Lyonbiopole competitivness cluster

Labels & Awards

PDCline_GATE_1

 

 

GATE1 Grenoble’s business incubator

 

i-LAB French national competition for the creation of innovative technologies companies
(French Ministry of Research)

 

 

 

Worldwide Innovation Challenge 2030
French “Investing for the Future Program”

 

 

 

 

French industrial plan for “medical biotechs”


 

Reseau Entreprendre / Inovizi

 

2015 Life Sciences Grand Prize of the French start-up competition Tremplin Entreprises

euflag

 

2016 This project has received funding from the European Union’s Horizon 2020 research and
innovation programme under grant agreement No 735097